Payload Information
General Information of This Payload
| Payload ID | PAY0AQACP |
|||||
|---|---|---|---|---|---|---|
| Name | Analogue of motolimod |
|||||
| Target(s) | Toll-like receptor 8 (TLR8) | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Pertuzumab zuvotolimod [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
7.10%
|
|||
| Patients Enrolled |
Patients have HER2-expressing or amplified solid tumors.
|
||||
| Administration Dosage |
0.60 mg/kg administered Q2 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04460456 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1/1b, open-label, dose escalation and expansion study of SBT6050 alone and in combination with PD-1 inhibitors in subjects with advanced solid tumors expressing HER2.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05091528 | Phase Status | Phase 1 | ||
| Clinical Description |
An open-label, phase 1/2, dose-escalation and expansion study of SBT6050 combined with other HER2-directed therapies in subjects with pretreated unresectable locally advanced and/or metastatic HER2-expressing or HER2-amplified cancers.
|
||||
References